Skip to content

Update on gene therapy clinical trial at Abeona and Stanford University

Abeona Therapeutics announces the publication of positive long-term data from Phase 1/2a clinical trial evaluating EB-101 gene therapy for recessive dystrophic Epidermolysis bullosa.

See publication here.

Back to main navigation
This website uses cookies to give you the best possible service. By using this website, you agree to the use of cookies. Detailed information can be found in our privacy policy .